Predicting response and survival in chemotherapy-treated triple-negative breast cancer

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1532-1541

  Prat, A ^a,b   Lluch, A ^c   Albanell, J ^d,e   Barry, W T ^f   Fan, C ^g   Chacon J I ^h   Parker, J S ^g,i   Calvo, L ^j   Plazaola, A ^k   Arcusa, A ^l   Segui Palmer M A ^m   Burgues, O ^c   Ribelles, N ⁿ   Rodriguez Lescure, A ^o   Guerrero, A ^p   Ruiz Borrego, M ^q   Munarriz, B ^r   Lopez J A ^s   Adamo, B ^a   Cheang, M C U ^g   Li, Y ^g   Hu, Z ^g   Gulley, M L ^g   Vidal, M J ^a   Pitcher, B N ^t   Liu, M C ^u   Citron, M L ^v   Ellis, M J ^w   Mardis, E ^w   Vickery, T ^w   Hudis, C A ^x   Winer, E P ^f   Carey, L A ^g   Caballero, R ^y   Carrasco, E ^y   Martin M ^y,z   Perou, C M ^g,i   Alba, E ⁿ   more..

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k Fundacion Onkologikoa   (Spain)

^l Brain   (Spain)

^m Hospital Universitari Parc Taulí   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^p INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^r HOSPITAL UNIVERSITARIO LA FE   (Spain)

^s Centro Asistencial San Camilo   (Spain)

^t DUKE UNIVERSITY   (United States)

^u MAYO CLINIC   (United States)

^v ProHEALTH Care Assoc LLP   (United States)

^w WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^y Hospital Universitario Gregorio Marañón ^*  (Spain)

^z HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COHORT ANALYSIS; FEMALE; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; SURVIVAL; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84908893016     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.444     Document Type: Review

References (45)

1. Adamo B, Anders C (2011) Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13: 105.
2. Alba E, Chacon J, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui M, Ribelles N, Alvarez R, Sanchez-Munoz A, Sanchez R, Garcia-Asenjo J, Rodriguez-Martin C, Escudero M, Albanell J (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136: 487-493.
3. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui M, Barley L, Boucher K, Alba E, Pappas L, Davis C, Aranda I, Fauron C, Stijleman I, Palacios J, Anton A, Carrasco E, Caballero R, Ellis M, Nielsen T, Perou C, Astill M, Bernard P, Martin M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5: 44.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
5. Cheang M, Martin M, Nielsen T, Prat A, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Voduc D, Bernard P, Ellis M, Perou C, Di Leo A, Carey L (2012) Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. Proceedings of the American Society of Clinical Oncology, 1-5 June 2012; Chicago, IL, USA, a1008.
6. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
7. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439.
8. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale A-L, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
9. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4: R60.
10. Fasching P, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer C, Rauh C, Schulz-Wendtland R, Bani M, Schrauder M, Kahmann L, Lux M, Strehl J, Hartmann A, Dimmler A, Beckmann M, Wachter D (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11: 486.
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795.
12. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, OShaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305: 1873-1881.
13. Hess KR, Anderson K, SymmansWF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
14. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30: 1996-2004.
15. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Ya-Hui Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3): 264-272.
16. Keam B, Im S, Lee K, Han S (2011) Ki-67 can be used for further classification of triple-negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13: R22.
17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
18. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281.
19. Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman P, Gradishar W, Perez E, Martino S, Citron M, Norton L, Winer E, Hudis C, Perou C, Ellis M, Barry W (2012) PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy. San Antonio Breast Cancer Symposium; 4-8 December 2012; San Antonio, TX, USA, P2-10-01.
20. Martón M, Rodróguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodróguez CA, Crespo C, de Alava E, López Garc?á-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguó MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegró A, Mel JR, Aranda E, Adrover E, A lvarez JV, Garc?á Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100: 805-814.
21. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19: 5533-5540.
22. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res 20: 782-790.
23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
24. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MCU, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifentreated estrogen receptor-positive breast cancer. Clin Cancer Res 16: 5222-5232.
25. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
26. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS (2010) Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 11: 718-719.
27. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
28. Popovici V, Chen W, Gallas B, Hatzis C, Shi W, Samuelson F, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12: R5.
29. Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM (2013a) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18: 123-133.
30. Prat A, Cheang MCU, Martón M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013b) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 31: 203-209.
31. Prat A, Parker J, Fan C, Perou C (2012) PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 135: 301-306.
32. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
33. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
34. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11: R15.
35. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13: R97.
36. Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E (2013) Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). San Antonio Breast Cancer Symposium; 10-14 December 2013; San Antonio, TX, USA, S5-01.
37. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, TungNM, DeNicolo A, Ganesan S,Miron A, Colin C, SgroiDC, Ellisen LW, Winer EP, Garber JE (2010a) Efficacy of neoadjuvant cisplatin in triplenegative breast cancer. J Clin Oncol 28: 1145-1153.
38. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010b) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153.
39. Skipper HE (1971) Kinetic behavior versus response to chemotherapy. Natl Cancer Inst Monogr 34: 2-14.
40. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botsein D, Eystein Lonning P, Borresen-Dale A (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
41. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16: 5351-5361.
42. Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MCU, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM (2013) Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 19: 4889-4899.
43. Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15: 747-756.
44. Whitfield M, George L, Grant G, Perou C (2006) Common markers of proliferation. Nat Rev Cancer 6: 99.
45. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2006) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.